Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026)
Fortrea Holdings (FTRE) reported Liabilities and Shareholders Equity of $2.7 billion for Q1 2026, down 14.02% on a YoY basis from $3.1 billion in Q1 2025, and down 1.19% quarter-over-quarter from $2.7 billion in Q4 2025.
Fortrea Holdings (FTRE) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $2.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 14.02% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $11.0 billion (down 21.2% YoY), and the FY2025 full-year result was $2.7 billion, down 24.13% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $2.7 billion, down from $2.7 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $4.4 billion in Q2 2023, with the low at $2.7 billion in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $3.6 billion across 5 years, with a median of $3.6 billion in 2024.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity climbed 1.04% — and 2025, when it fell 26.39%.
- Fortrea Holdings' Liabilities and Shareholders Equity stood at $4.3 billion in 2022, then gained by 1.04% to $4.3 billion in 2023, then declined by 17.39% to $3.6 billion in 2024, then fell by 24.13% to $2.7 billion in 2025, then slipped by 1.19% to $2.7 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $2.7 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 2.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.74 Bn |
| Jun 30, 2025 | 2.84 Bn |
| Mar 31, 2025 | 3.12 Bn |
| Dec 31, 2024 | 3.58 Bn |
| Sep 30, 2024 | 3.66 Bn |
| Jun 30, 2024 | 3.57 Bn |
| Mar 31, 2024 | 4.24 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Sep 30, 2023 | 4.32 Bn |
| Jun 30, 2023 | 4.36 Bn |
| Dec 31, 2022 | 4.29 Bn |